The Smart Car (Avastin) vs. the Lexus (Eylea). They both get you there but one costs a lot more.

A recent study showed Avastin ($60 per dose, used off-label) was just as effective as Eylea ($1850 per dose, FDA approved treatment) in terms of visual acuity for the treatment of CRVO.
The Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) evaluated the safety and efficacy of the two drugs. In the study, patients received either an Avastin or Eylea injection every 4 weeks for 6 months.  At the six month follow up, visual acuity improved from 20/100 to 20/40 for both groups and the rates of adverse events, such as elevated intraocular pressure, were low and similar in both groups. (via)